Vivimed Labs Limited (NSE:VIVIMEDLAB)
India flag India · Delayed Price · Currency is INR
5.55
-0.29 (-4.97%)
At close: Mar 27, 2026

Vivimed Labs Cash Flow Statement

Millions INR. Fiscal year is Apr - Mar.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '25 Mar '24 Mar '23 Mar '22 Mar '21
Net Income
-319.61-454.46-3,285-676.5-718.86
Depreciation & Amortization
202.24199.41191.27182.82554.95
Asset Writedown & Restructuring Costs
--892.8--
Other Operating Activities
33.49165.5337.89431.35750.66
Change in Accounts Receivable
87.1-86.64105.54201.391,416
Change in Inventory
53.07156.981,610149.172,462
Change in Accounts Payable
-46.44-111.62275.1976.42-1,922
Change in Income Taxes
-1.78----
Change in Other Net Operating Assets
-25.58-109.08225.83-89.253,131
Operating Cash Flow
-17.51-239.91353.22275.45,673
Operating Cash Flow Growth
--28.26%-95.14%612.93%
Capital Expenditures
-45.31-20.39-49.68-164.1-
Sale of Property, Plant & Equipment
----5,171
Investment in Securities
-303.26---1,131
Investing Cash Flow
-45.31282.87-49.68-164.14,040
Short-Term Debt Issued
80--224.56-
Long-Term Debt Issued
--21.2169.26-
Total Debt Issued
80-21.21293.82-
Short-Term Debt Repaid
-----2,233
Long-Term Debt Repaid
-0.89-36---4,130
Total Debt Repaid
-0.89-36---6,362
Net Debt Issued (Repaid)
79.11-3621.21293.82-6,362
Other Financing Activities
-29.47-24.33-359.03-397.61-3,791
Financing Cash Flow
49.64-60.33-337.82-103.79-10,153
Miscellaneous Cash Flow Adjustments
--0.060.02-0.02
Net Cash Flow
-13.18-17.37-34.227.53-440.58
Free Cash Flow
-62.82-260.3303.54111.35,673
Free Cash Flow Growth
--172.72%-98.04%-
Free Cash Flow Margin
-5.21%-16.37%16.14%4.67%65.11%
Free Cash Flow Per Share
-0.76-3.143.661.3468.42
Cash Interest Paid
29.4724.32359.03397.6538.76
Cash Income Tax Paid
-0.910.94---250.7
Levered Free Cash Flow
97.2-254.94607.08-134.381,973
Unlevered Free Cash Flow
108.05-247.35825.86106.52,289
Change in Working Capital
66.37-150.362,217337.735,086
Source: S&P Global Market Intelligence. Standard template. Financial Sources.